Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

• Published in: The New England journal of medicine Vol. 379; no. 24; pp. 2342 - 2350
• Main Authors: Antonia, Scott J, Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Hui, Rina, Kurata, Takayasu, Chiappori, Alberto, Lee, Ki H, de Wit, Maike, Cho, Byoung C, Bourhaba, Maryam, Quantin, Xavier, Tokito, Takaaki, Mekhail, Tarek, Planchard, David, Kim, Young-Chul, Karapetis, Christos S, Hiret, Sandrine, Ostoros, Gyula, Kubota, Kaoru, Gray, Jhanelle E, Paz-Ares, Luis, de Castro Carpeño, Javier, Faivre-Finn, Corinne, Reck, Martin, Vansteenkiste, Johan, Spigel, David R, Wadsworth, Catherine, Melillo, Giovanni, Taboada, Maria, Dennis, Phillip A, Özgüroğlu, Mustafa
• Format: Journal Article Web Resource
• Language: English
• Published: United States Massachusetts Medical Society 13.12.2018
• Subjects: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal/administration & dosage/adverse effects; Antineoplastic Agents, Immunological - administration & dosage; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological/administration & dosage/adverse effects; Body weight; Cancer; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - radiotherapy; Carcinoma, Non-Small-Cell Lung/drug therapy/mortality/radiotherapy; Chemoradiotherapy; Chemotherapy; Death; Disease control; Female; Human health and pathology; Human health sciences; Humans; Immunotherapy; Infusions, Intravenous; Intention to Treat Analysis; Kaplan-Meier Estimate; Life Sciences; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Lung Neoplasms - radiotherapy; Lung Neoplasms/drug therapy/mortality/radiotherapy; Male; Metastases; Metastasis; Middle Aged; Monoclonal antibodies; Non-small cell lung carcinoma; Oncologie; Oncology; Radiation therapy; Response rates; Sciences de la santé humaine; Smoking; Survival Rate; Targeted cancer therapy
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa1809697

In patients with locally advanced non–small-cell lung cancer who have undergone concurrent chemotherapy and radiation therapy, the use of durvalumab in the year after completing treatment significantly prolonged disease-free and overall survival as compared with placebo.